Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer

被引：0
|
作者：
Cochereau, D. [1 ]
Cottu, P. [1 ]
机构：
[1] Inst Curie, F-75005 Paris, France
来源：
ONCOLOGIE | 2015年 / 17卷 / 04期
关键词：
CHEMOTHERAPY;
D O I：
10.1007/s10269-015-2511-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：194 / 196
页数：3
相关论文
共 50 条
  • [21] Impact of adjuvant trastuzumab (T) with chemotherapy on breast cancer specific and cardiac outcomes in older women with small, node-negative HER2-positive breast cancer
    Cadoo, K. A.
    Morris, P. G.
    Patil, S.
    Norton, L.
    Hudis, C. A.
    McArthur, H. L.
    CANCER RESEARCH, 2013, 73
  • [22] Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC).
    Iyengar, Neil M.
    Fornier, Monica Nancy
    Sugarman, Steven
    Theodoulou, Maria
    Troso-Sandoval, Tiffany A.
    D'Andrea, Gabriella
    Drullinsky, Pamela
    Fasano, Julie
    Gajria, Devika
    Goldfarb, Shari Beth
    Comen, Elizabeth Anne
    Lake, Diana
    Modi, Shanu
    Traina, Tiffany A.
    Chen, Melanie
    Patil, Sujata
    Baselga, Jose
    Norton, Larry
    Hudis, Clifford A.
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer
    不详
    GYNAKOLOGE, 2016, 49 (08): : 558 - 558
  • [24] Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer
    Cadoo, Karen A.
    Morris, Patrick G.
    Cowell, Elizabeth P.
    Patil, Sujata
    Hudis, Clifford A.
    McArthur, Heather L.
    CLINICAL BREAST CANCER, 2016, 16 (06) : 487 - 493
  • [25] Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study
    Hassing, Christina M. S.
    Mejdahl, Mathias Kvist
    Laenkholm, Anne-Vibeke
    Kroman, Niels
    Knoop, Ann Soegaard
    Tvedskov, Tove Holst Filtenborg
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 196 (01) : 197 - 206
  • [26] Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study
    Christina M. S. Hassing
    Mathias Kvist Mejdahl
    Anne-Vibeke Lænkholm
    Niels Kroman
    Ann Søegaard Knoop
    Tove Holst Filtenborg Tvedskov
    Breast Cancer Research and Treatment, 2022, 196 : 197 - 206
  • [27] Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)
    Tolaney, Sara M.
    Barry, William Thomas
    Guo, Hao
    Dillon, Deborah
    Dang, Chau T.
    Yardley, Denise A.
    Moy, Beverly
    Marcom, P. Kelly
    Albain, Kathy S.
    Rugo, Hope S.
    Ellis, Matthew James
    Shapira, Iuliana
    Wolff, Antonio C.
    Carey, Lisa A.
    Overmoyer, Beth
    Partridge, Ann H.
    Hudis, Clifford A.
    Krop, Ian E.
    Burstein, Harold J.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?
    Lin, Haiping
    Zheng, Hongjuan
    Ge, Chenyang
    Wang, Qinghua
    Tang, Wanfen
    Zhang, Xia
    Zhou, Shishi
    Jin, Xiayun
    Xu, Xifeng
    Du, Jinlin
    Fu, Jianfei
    CLINICAL BREAST CANCER, 2020, 20 (06) : 503 - 510
  • [29] Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
    Joerger, M.
    Thuerlimann, B.
    Huober, J.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 17 - 23
  • [30] Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer
    Sonke, Gabe S.
    Mandjes, Ingrid A.
    Holtkamp, Marjo J.
    Schot, Margaret
    van Werkhoven, Erik
    Wesseling, Jelle
    Peeters, Marie-Jeanne Vrancken
    Rodenhuis, Sjoerd
    Linn, Sabine C.
    BREAST JOURNAL, 2013, 19 (04): : 419 - 426
12345